title: Availability of glucose ingested during muscle exercise performed under acipimox-induced lipolysis blockade.
abstract: This study investigated the percentage of carbohydrate utilization than can be accounted for by glucose ingested during exercise performed after the ingestion of the potent lipolysis inhibitor Acipimox. Six healthy male volunteers exercised for 3 h on a treadmill at about 45% of their maximal oxygen uptake, 75 min after having ingested 250 mg of Acipimox. After 15-min adaptation to exercise, they ingested either glucose dissolved in water, 50 g at time 0 min and 25 g at time 60 and 120 min (glucose, G) or sweetened water (control, C). Naturally labelled [13C]glucose was used to follow the conversion of the ingested glucose to expired-air CO2. Acipimox inhibited lipolysis in a similar manner in both experimental conditions. This was reflected by an almost complete suppression of the exercise-induced increase in plasma free fatty acid and glycerol and by an almost constant rate of lipid oxidation. Total carbohydrate oxidation evaluated by indirect calorimetry, was similar in both experimental conditions [C, 182, (SEM 21); G, 194 (SEM 16) g.3 h-1], as was lipid oxidation [C, 57 (SEM 6); G, 61 (SEM 3) g.3 h-1]. Exogenous glucose oxidation during exercise G, calculated by the changes in 13C:12C ratio of expired air CO2, averaged 66 (SEM 5) g.3 h-1 (19% of the total energy requirement). Consequently, endogenous carbohydrate utilization was significantly smaller after glucose than after placebo ingestion: 128 (SEM 18) versus 182 (SEM 21) g.3 h-1, respectively (P < 0.05). Symptoms of intense fatigue and leg cramps observed with intake of sweet placebo were absent with glucose ingestion.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, University of Liège, Belgium.
authors.forename: J F
authors.initials: JF
authors.lastname: Gautier
authors.forename: F
authors.initials: F
authors.lastname: Pirnay
authors.forename: B
authors.initials: B
authors.lastname: Jandrain
authors.forename: M
authors.initials: M
authors.lastname: Lacroix
authors.forename: F
authors.initials: F
authors.lastname: Mosora
authors.forename: A J
authors.initials: AJ
authors.lastname: Scheen
authors.forename: G
authors.initials: G
authors.lastname: Cathelineau
authors.forename: P J
authors.initials: PJ
authors.lastname: Lefèbvre
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood; D002153:Calorimetry, Indirect; D050260:Carbohydrate Metabolism; D004734:Energy Metabolism; D005934:Glucagon / Q000097:blood; D005947:Glucose / Q000008:administration & dosage* / Q000378:metabolism*; D005990:Glycerol / Q000097:blood; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology; D007328:Insulin / Q000097:blood; D050356:Lipid Metabolism; D008066:Lipolysis / Q000187:drug effects*; D008297:Male; D010084:Oxidation-Reduction; D005082:Physical Exertion / Q000502:physiology*; D011719:Pyrazines / Q000494:pharmacology*
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D000960:Hypolipidemic Agents; D007328:Insulin; D011719:Pyrazines; D005934:Glucagon; D005947:Glucose; C027696:acipimox; D005990:Glycerol